Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD.
- Resource Type
- Article
- Source
- International Journal of COPD; Apr2018, Vol. 13, p1187-1194, 8p, 2 Diagrams, 3 Charts
- Subject
- Language
- ISSN
- 11769106